Abstract

A series of novel 2′-tetrazolyl- and 2′-carboxy-biphenylylmethyl-pyrrolidine derivatives (VIIIa–d, IX, X, XIa–d, XII, XIII, XIVa–d, XV ,and XVI) were designed and evaluated as Ang II AT1 receptor antagonists. The compare/fit scores of these molecules were determined using an Ang II AT1 receptor antagonist hypothesis constructed from known antagonists using CATALYST/DS modules and demonstrated significantly high simulated fit values. These hit molecules were subsequently synthesized and their in vivo antihypotensive and antihypertensive activities evaluated in normotensive cats and rats, and hypertensive rats. Compounds XII, XIII, XV, and XVI showed lower or similar levels of activity to the reference compound losartan. In contrast, the activities of compounds X and IX were 1.5- and 2-fold higher than losartan. Furthermore, the LD50 value for IX was determined to be 117 µg/Kg, indicating its high safety margin.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.